Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: A retrospective case-control study

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 299-302

  Mason, Brendan W ^a   Howard, Anthony J ^b  

^a PUBLIC HEALTH WALES   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Antimicrobial resistance; Case control study; Fusidic acid; Methicillin susceptible Staphylococcus aureus

Indexed keywords

CHLORTETRACYCLINE; FUSIDIC ACID; METICILLIN; METRONIDAZOLE; NEOMYCIN; OXYTETRACYCLINE; POLYMYXIN; PSEUDOMONIC ACID; SULFADIAZINE SILVER;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CASE CONTROL STUDY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

EID: 1442360926     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.013     Document Type: Article

References (16)

1. Brown E.M., Wise R. Fusidic acid should be used with restraint. Br. Med. J. 324:2002;1394.
2. Mason B.W., Howard A.J., Magee J.T. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob. Chemother. 51:2003;1033-1036.
3. Epidemiology Program Office. Epi Info Version 6. Atlanta: Centers for Disease Control and Prevention; 2001.
4. StataCorp. Stata Statistical Software: Release 7.0. Texas: Stata Corporation; 2001.
5. Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance. The path of least resistance. London: Department of Health; 1998.
6. Colligon P., Turnidge J. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents. 12:1999;s45-s58.
7. Ravenscroft J.C., Layton A., Barnham M. Observations of high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin. Exp. Dermatol. 25:2000;327-330.
8. Pattison J.R., Mansell P.E. Fucidin-resistant staphylococci in current hospital practice. J. Med. Microbiol. 6:1973;235-244.
9. Lowbury E.J.L., Cason J.S., Jackson D.M., Miller R.W.S. Fucidin for staphylococcal infection of burns. Lancet. ii:1962;478-480.
10. Ritchie IC. Economic aspects of surface sepsis: a trial of fucicin ointment. Clin Trials J 1966;529-31.
11. Wilkinson J.D., Leigh D., Menday A.P. Comparative efficacy of betamethasone and either fusidic acid or neomycin in infected or potentially infected eczema. Curr. Ther. Res. 38:1985;177-182.
12. Gillett A.P., Johnson T., Orton C., Willis R., Menday A.P., Talbot D.J. Nasal carriage and antibiotic susceptibility of Staphylococcus aureus in general practice. J. R. Coll. Gen. Pract. 34:1984;255-257.
13. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown and Company; 1987.
14. Kristiansen B.E., Tveten Y., Jenkins A. Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study. Br. Med. J. 317:1998;621-625.
15. Parry S.M., Salmon R L. Sporadic STEC O157 infection: secondary household transmission in Wales. Emerg. Infect. Dis. 4:1988;656-657.
16. O'Neil A.J., Cove J.H., Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J. Antimicrob. Chemother. 47:2001;647-650.